首页 > 最新文献

Journal of Infection最新文献

英文 中文
Identification of a long-standing HIV-1 circulating recombinant form (CRF178_BC) in different high-risk populations along the China-Myanmar border region 中缅边境地区不同高危人群长期存在的HIV-1循环重组形式(CRF178_BC)的鉴定
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-21 DOI: 10.1016/j.jinf.2025.106477
Min Chen , Yanling Ma, , Huichao Chen, Manhong Jia, Wenfei Ding
{"title":"Identification of a long-standing HIV-1 circulating recombinant form (CRF178_BC) in different high-risk populations along the China-Myanmar border region","authors":"Min Chen , Yanling Ma, , Huichao Chen, Manhong Jia, Wenfei Ding","doi":"10.1016/j.jinf.2025.106477","DOIUrl":"10.1016/j.jinf.2025.106477","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106477"},"PeriodicalIF":14.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid spread of Candida auris in China after COVID-19 2019冠状病毒病后,耳念珠菌在中国迅速传播。
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-21 DOI: 10.1016/j.jinf.2025.106476
Jian Bing , Yanfeng Huang , Han Du, , Penghao Guo , Junmin Cao, Mei Kang, Clarissa J. Nobile, Guanghua Huang
{"title":"Rapid spread of Candida auris in China after COVID-19","authors":"Jian Bing , Yanfeng Huang , Han Du, , Penghao Guo , Junmin Cao, Mei Kang, Clarissa J. Nobile, Guanghua Huang","doi":"10.1016/j.jinf.2025.106476","DOIUrl":"10.1016/j.jinf.2025.106476","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106476"},"PeriodicalIF":14.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands 荷兰2022/2023年呼吸道季节SARS-CoV-2与呼吸道病毒共感染动态
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-21 DOI: 10.1016/j.jinf.2025.106474
Gesa Carstens , Eva Kozanli , Kirsten Bulsink, Scott A. McDonald, Mansoer Elahi, Jordy de Bakker, Maarten Schipper, Rianne van Gageldonk-Lafeber, Susan van den Hof, Albert Jan van Hoek, Dirk Eggink

Objectives

Evaluation of the presence and effect of SARS-CoV-2 co-infections on disease severity.

Methods

We collected both symptom data and nose- and throat samples from symptomatic people during the 2022/2023 respiratory season in a large participatory surveillance study in the Netherlands, and tested these for 18 respiratory viruses, including SARS-CoV-2. We compared reported health status, symptoms and odds of having a single respiratory viral infection or co-infection with SARS-CoV-2 and another respiratory virus.

Results

In total, 4655 samples were included with 22% (n=1017) testing SARS-CoV-2 positive. Of these 11% (n=116) also tested positive for a second respiratory virus. The most frequently occurring co-infections in SARS-CoV-2 positive participants were with rhinovirus (59%; n=69), seasonal coronaviruses (15%; n=17), and adenovirus (7%; n=8). Participants with a co-infection with one of these three viruses did not report more severe disease compared to those with a SARS-CoV-2 mono-infection. The odds of experiencing SARS-CoV-2 co-infection with seasonal coronavirus or rhinovirus were lower compared to the odds of the respective non-SARS-CoV-2 mono-infection (OR: 0.16, CI 95%: 0.10 – 0.24; OR: 0.21 CI 95%: 0.17 – 0.26; respectively).

Conclusions

SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus, and adenovirus are frequently observed in the general population, but are not associated with more severe disease compared to SARS-CoV-2 mono-infections. Furthermore, we found indications for inter-virus interaction with rhinovirus and seasonal coronavirus, possibly decreasing the risk of co-infection.
目的:评价SARS-CoV-2合并感染对疾病严重程度的影响。方法:在荷兰进行的一项大型参与性监测研究中,我们收集了2022/2023呼吸道季节有症状人群的症状数据和鼻咽喉样本,并对包括SARS-CoV-2在内的18种呼吸道病毒进行了检测。我们比较了报告的健康状况、症状和患单呼吸道病毒感染或合并感染SARS-CoV-2和另一种呼吸道病毒的几率。结果:共纳入4655份样本,其中22% (n= 1017)呈SARS-CoV-2阳性。其中11% (n=116)的第二呼吸道病毒检测呈阳性。在SARS-CoV-2阳性参与者中,最常见的合并感染是鼻病毒(59%;N =69),季节性冠状病毒(15%;N =17)和腺病毒(7%;n = 8)。与SARS-CoV-2单一感染的参与者相比,同时感染这三种病毒之一的参与者没有报告更严重的疾病。SARS-CoV-2合并季节性冠状病毒或鼻病毒感染的几率低于各自非SARS-CoV-2单一感染的几率(or: 0.16, CI 95%: 0.10 - 0.24;Or: 0.21 ci 95%: 0.17 - 0.26;分别)。结论:SARS-CoV-2与鼻病毒、季节性冠状病毒和腺病毒合并感染在普通人群中常见,但与SARS-CoV-2单一感染相比,其病情并不严重。此外,我们发现了病毒间与鼻病毒和季节性冠状病毒相互作用的迹象,可能降低了合并感染的风险。
{"title":"Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands","authors":"Gesa Carstens ,&nbsp;Eva Kozanli ,&nbsp;Kirsten Bulsink,&nbsp;Scott A. McDonald,&nbsp;Mansoer Elahi,&nbsp;Jordy de Bakker,&nbsp;Maarten Schipper,&nbsp;Rianne van Gageldonk-Lafeber,&nbsp;Susan van den Hof,&nbsp;Albert Jan van Hoek,&nbsp;Dirk Eggink","doi":"10.1016/j.jinf.2025.106474","DOIUrl":"10.1016/j.jinf.2025.106474","url":null,"abstract":"<div><h3>Objectives</h3><div>Evaluation of the presence and effect of SARS-CoV-2 co-infections on disease severity.</div></div><div><h3>Methods</h3><div>We collected both symptom data and nose- and throat samples from symptomatic people during the 2022/2023 respiratory season in a large participatory surveillance study in the Netherlands, and tested these for 18 respiratory viruses, including SARS-CoV-2. We compared reported health status, symptoms and odds of having a single respiratory viral infection or co-infection with SARS-CoV-2 and another respiratory virus.</div></div><div><h3>Results</h3><div>In total, 4655 samples were included with 22% (n=1017) testing SARS-CoV-2 positive. Of these 11% (n=116) also tested positive for a second respiratory virus. The most frequently occurring co-infections in SARS-CoV-2 positive participants were with rhinovirus (59%; n=69), seasonal coronaviruses (15%; n=17), and adenovirus (7%; n=8). Participants with a co-infection with one of these three viruses did not report more severe disease compared to those with a SARS-CoV-2 mono-infection. The odds of experiencing SARS-CoV-2 co-infection with seasonal coronavirus or rhinovirus were lower compared to the odds of the respective non-SARS-CoV-2 mono-infection (OR: 0.16, CI 95%: 0.10 – 0.24; OR: 0.21 CI 95%: 0.17 – 0.26; respectively).</div></div><div><h3>Conclusions</h3><div>SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus, and adenovirus are frequently observed in the general population, but are not associated with more severe disease compared to SARS-CoV-2 mono-infections. Furthermore, we found indications for inter-virus interaction with rhinovirus and seasonal coronavirus, possibly decreasing the risk of co-infection.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 5","pages":"Article 106474"},"PeriodicalIF":14.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections 接种后IgG4和IgG2类转换与SARS-CoV-2感染风险增加相关
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-18 DOI: 10.1016/j.jinf.2025.106473
Carla Martín Pérez , Sílvia Ruiz-Rius , Anna Ramírez-Morros , Marta Vidal , D. Herbert Opi , Pere Santamaria , Julià Blanco , Josep Vidal-Alaball , James G. Beeson , Luis M. Molinos-Albert , Ruth Aguilar , Anna Ruiz-Comellas , Gemma Moncunill , Carlota Dobaño

Objectives

Repeated COVID-19 mRNA vaccinations increase SARS-CoV-2 IgG4 antibodies, indicating extensive IgG class switching following the first booster dose. This shift in IgG subclasses raises concerns due to the limited ability of IgG4 to mediate Fc-dependent effector functions.

Methods

To assess the impact of IgG4 induction on protective immunity, we analyzed longitudinal SARS-CoV-2 IgG subclasses, C1q and FcγR responses, and neutralizing activity in a well-characterized cohort of healthcare workers in Spain.

Results

Elevated IgG4 levels and higher ratios of non-cytophilic to cytophilic antibodies after booster vaccination were significantly associated with an increased risk of breakthrough infections (IgG4 HR[10-fold increase]=1.8, 95% CI=1.2–2.7; non-cytophilic to cytophilic ratio HR[10-fold increase]=1.5, 95% CI=1.1–1.9). Moreover, an increased non-cytophilic to cytophilic antibody ratio correlated with reduced functionality, including neutralization.

Conclusions

These findings suggest a potential association between IgG4 induction by mRNA vaccination and a higher risk of breakthrough infection, warranting further investigation into vaccination strategies to ensure sustained protection.
目的重复接种COVID-19 mRNA疫苗会增加SARS-CoV-2 IgG4抗体,这表明在接种第一针加强剂量后IgG亚类发生了广泛的转换。由于 IgG4 介导 Fc 依赖性效应器功能的能力有限,IgG 亚类的这种转变令人担忧:为了评估 IgG4 诱导对保护性免疫的影响,我们分析了西班牙一批特征明确的医护人员的纵向 SARS-CoV-2 IgG 亚类、C1q 和 FcγR 反应以及中和活性:加强免疫后 IgG4 水平升高和非嗜细胞抗体与嗜细胞抗体比率升高与突破性感染风险增加有显著相关性(IgG4 HR[10 倍增长]=1.8,95% CI=1.2-2.7;非嗜细胞抗体与嗜细胞抗体比率 HR[10 倍增长]=1.5,95% CI=1.1-1.9)。此外,非嗜细胞抗体与嗜细胞抗体比率的增加与包括中和在内的功能降低有关:这些研究结果表明,mRNA 疫苗接种诱导 IgG4 与更高的突破性感染风险之间存在潜在联系,因此有必要进一步研究疫苗接种策略,以确保持续的保护。
{"title":"Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections","authors":"Carla Martín Pérez ,&nbsp;Sílvia Ruiz-Rius ,&nbsp;Anna Ramírez-Morros ,&nbsp;Marta Vidal ,&nbsp;D. Herbert Opi ,&nbsp;Pere Santamaria ,&nbsp;Julià Blanco ,&nbsp;Josep Vidal-Alaball ,&nbsp;James G. Beeson ,&nbsp;Luis M. Molinos-Albert ,&nbsp;Ruth Aguilar ,&nbsp;Anna Ruiz-Comellas ,&nbsp;Gemma Moncunill ,&nbsp;Carlota Dobaño","doi":"10.1016/j.jinf.2025.106473","DOIUrl":"10.1016/j.jinf.2025.106473","url":null,"abstract":"<div><h3>Objectives</h3><div>Repeated COVID-19 mRNA vaccinations increase SARS-CoV-2 IgG4 antibodies, indicating extensive IgG class switching following the first booster dose. This shift in IgG subclasses raises concerns due to the limited ability of IgG4 to mediate Fc-dependent effector functions.</div></div><div><h3>Methods</h3><div>To assess the impact of IgG4 induction on protective immunity, we analyzed longitudinal SARS-CoV-2 IgG subclasses, C1q and FcγR responses, and neutralizing activity in a well-characterized cohort of healthcare workers in Spain.</div></div><div><h3>Results</h3><div>Elevated IgG4 levels and higher ratios of non-cytophilic to cytophilic antibodies after booster vaccination were significantly associated with an increased risk of breakthrough infections (IgG4 HR[10-fold increase]=1.8, 95% CI=1.2–2.7; non-cytophilic to cytophilic ratio HR[10-fold increase]=1.5, 95% CI=1.1–1.9). Moreover, an increased non-cytophilic to cytophilic antibody ratio correlated with reduced functionality, including neutralization.</div></div><div><h3>Conclusions</h3><div>These findings suggest a potential association between IgG4 induction by mRNA vaccination and a higher risk of breakthrough infection, warranting further investigation into vaccination strategies to ensure sustained protection.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106473"},"PeriodicalIF":14.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating lncRNAs as biomarkers for severe dengue using a machine learning approach 使用机器学习方法循环lncrna作为严重登革热的生物标志物。
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-14 DOI: 10.1016/j.jinf.2025.106471
Rodolfo Katz , Nguyen Minh Nam , Tulio de Lima Campos , Victoria Indenbaum , Sophie Terenteva , Dinh Thi Thu Hang , Le Thi Hoi , Amos Danielli , Yaniv Lustig , Eli Schwartz , Hoang Van Tong , Ella H. Sklan

Objectives

Dengue virus (DENV) infection is a significant global health concern, causing severe morbidity and mortality. While many cases present as a mild febrile illness, some progress to life-threatening severe dengue (SD). Early intervention is essential to improve outcomes, but current predictive methods lack specificity, burdening healthcare systems in endemic regions. Circulating long non-coding RNAs (lncRNAs) have emerged as stable and promising biomarkers. This study explored the use of lncRNAs as predictive markers for SD.

Methods

Differential expression and qPCR arrays were employed to identify lncRNAs associated with SD. Candidate lncRNAs were validated, and their plasma levels were measured in a cohort of Vietnamese dengue patients (n =377) and healthy controls (n=128) at admission. Machine learning algorithms were applied to predict the probability of SD progression.

Results

The predictive model demonstrated high sensitivity and specificity, with an area under the curve (AUC) of 0.98 (95% CI: 0.96–1.0). At admission, it accurately identified 17 of 18 patients who later died as high-risk, compared to traditional warning signs, which flagged only 9 of these cases.

Conclusions

Our findings suggest that this panel of lncRNAs has the potential to predict SD, which could help reduce healthcare burden and improve patient management in endemic countries.
目的:登革热病毒(DENV)感染是一个重大的全球卫生问题,造成严重的发病率和死亡率。虽然许多病例表现为轻度发热性疾病,但有些进展为危及生命的严重登革热(SD)。早期干预对改善结果至关重要,但目前的预测方法缺乏特异性,给流行地区的卫生保健系统带来负担。循环长链非编码rna (lncRNAs)已成为一种稳定且有前景的生物标志物。本研究探讨了lncrna作为SD的预测标记物的使用。方法:采用差异表达和qPCR阵列鉴定与SD相关的lncrna。对候选lncrna进行验证,并在入院时在越南登革热患者(n= 377)和健康对照(n=128)中测量其血浆水平。应用机器学习算法预测SD进展的概率。结果:该预测模型具有较高的敏感性和特异性,曲线下面积(AUC)为0.98 (95% CI: 0.96 ~ 1.0)。入院时,它准确地识别了18名患者中的17名,这些患者后来死亡为高风险,而传统的警告标志只标记了其中的9例。结论:我们的研究结果表明,这组lncrna具有预测SD的潜力,可以帮助减轻流行国家的医疗负担并改善患者管理。
{"title":"Circulating lncRNAs as biomarkers for severe dengue using a machine learning approach","authors":"Rodolfo Katz ,&nbsp;Nguyen Minh Nam ,&nbsp;Tulio de Lima Campos ,&nbsp;Victoria Indenbaum ,&nbsp;Sophie Terenteva ,&nbsp;Dinh Thi Thu Hang ,&nbsp;Le Thi Hoi ,&nbsp;Amos Danielli ,&nbsp;Yaniv Lustig ,&nbsp;Eli Schwartz ,&nbsp;Hoang Van Tong ,&nbsp;Ella H. Sklan","doi":"10.1016/j.jinf.2025.106471","DOIUrl":"10.1016/j.jinf.2025.106471","url":null,"abstract":"<div><h3>Objectives</h3><div>Dengue virus (DENV) infection is a significant global health concern, causing severe morbidity and mortality. While many cases present as a mild febrile illness, some progress to life-threatening severe dengue (SD). Early intervention is essential to improve outcomes, but current predictive methods lack specificity, burdening healthcare systems in endemic regions. Circulating long non-coding RNAs (lncRNAs) have emerged as stable and promising biomarkers. This study explored the use of lncRNAs as predictive markers for SD.</div></div><div><h3>Methods</h3><div>Differential expression and qPCR arrays were employed to identify lncRNAs associated with SD. Candidate lncRNAs were validated, and their plasma levels were measured in a cohort of Vietnamese dengue patients (<span><math><mi>n</mi></math></span> =377) and healthy controls (<span><math><mi>n</mi></math></span>=128) at admission. Machine learning algorithms were applied to predict the probability of SD progression.</div></div><div><h3>Results</h3><div>The predictive model demonstrated high sensitivity and specificity, with an area under the curve (AUC) of 0.98 (95% CI: 0.96–1.0). At admission, it accurately identified 17 of 18 patients who later died as high-risk, compared to traditional warning signs, which flagged only 9 of these cases.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that this panel of lncRNAs has the potential to predict SD, which could help reduce healthcare burden and improve patient management in endemic countries.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106471"},"PeriodicalIF":14.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term risk of psychiatric disorders in childhood and adolescence following neonatal invasive group B Streptococcus disease—A Danish cohort study 新生儿侵袭性B组链球菌病后儿童和青少年精神障碍的长期风险——丹麦队列研究
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-13 DOI: 10.1016/j.jinf.2025.106463
Malene Risager Lykke , Henrik Toft Sørensen , Joy Elisabeth Lawn , Erzsébet Horváth-Puhó

Objectives

The long-term risk of child and adolescent psychiatric disorders (PDs) after neonatal invasive group B Streptococcus disease (iGBS) and the modifying factors are poorly understood.

Methods

A population-based matched cohort study, including 1548 infants with iGBS diagnosed during the first 3 months of life from 1997 through 2020 and follow-up until 2022, based on data from Danish national health and administrative registers. A general population comparison cohort of infants without iGBS was randomly sampled and matched 1:10 by sex, the child’s birth year and month, and gestational age (n= 15,345).

Results

The cumulative incidence proportion (CIP) with 95% confidence intervals (CIs) of any PD was 21.1% (95% CI 18.7–23.7) in infants exposed to iGBS (88% sepsis, 12% meningitis) and 16.2% (95% CI 15.5–17.0) in the comparison cohort. The 18-year CIP of PD was higher for infants exposed to iGBS meningitis compared to iGBS sepsis. The adjusted hazard ratio for PD in infants with iGBS was 1.41 (95% CI 1.23–1.62).

Conclusions

iGBS in early infancy is a risk factor for PDs, especially iGBS meningitis. Premature birth, gestational diabetes, and low maternal education increased the risk of any PD further.

Summary

Group B Streptococcus (Streptococcus agalactiae) remains the leading cause of neonatal, invasive disease and is associated with high mortality and risk of neurodevelopmental impairments. Scarce data exist regarding the long-term risk of psychiatric disorders following invasive group B Streptococcus disease in early infancy (iGBS), especially following sepsis. In this Danish national cohort study, we investigated the association of iGBS and the risk of psychiatric disorders until adolescence and early adulthood. We investigated to which extent premature birth, sex (at birth), maternal socioeconomic position or gestational diabetes were modifying the association between iGBS and psychiatric disorders.
Our study found an increased risk of psychiatric disorders persisting into adolescence following iGBS, including both meningitis and sepsis. Specific psychiatric disorders with elevated risk included anxiety, obsessive-compulsive disorder, autism, and attention deficit hyperactivity disorder. Premature birth, maternal gestational diabetes, and low maternal education further increased the risk of any psychiatric disorders, whereas the child’s sex did not.
目的:新生儿侵袭性B族链球菌病(iGBS)后儿童和青少年精神障碍(pd)的长期风险及其影响因素尚不清楚。方法:基于丹麦国家卫生和行政登记处的数据,一项基于人群的匹配队列研究,包括1997年至2020年出生后3个月内诊断为iGBS的1,548名婴儿,并随访至2022年。无iGBS婴儿的一般人群比较队列随机抽样,按性别、孩子的出生年月日和胎龄1:10匹配(n= 15,345)。结果:在暴露于iGBS(88%败血症,12%脑膜炎)的婴儿中,任何PD的累积发病率(CIP)与95%置信区间(CIs)为21.1% (95% CI 18.7-23.7),而在比较队列中为16.2% (95% CI 15.5-17.0)。与iGBS败血症相比,暴露于iGBS脑膜炎的婴儿18年PD的CIP更高。iGBS患儿PD的校正危险比为1.41 (95% CI 1.23-1.62)。结论:婴儿期早期iGBS是PDs的危险因素,尤其是iGBS脑膜炎。早产、妊娠期糖尿病和低母亲教育水平进一步增加了任何PD的风险。B族链球菌(无乳链球菌)仍然是新生儿侵袭性疾病的主要原因,并与高死亡率和神经发育障碍风险相关。关于早期婴儿(iGBS)侵袭性B族链球菌病(iGBS)后精神障碍的长期风险,特别是败血症的数据很少。在这项丹麦国家队列研究中,我们调查了iGBS与青春期和成年早期精神疾病风险的关系。我们调查了早产、性别(出生时)、母亲的社会经济地位或妊娠期糖尿病在多大程度上改变了iGBS和精神疾病之间的关联。我们的研究发现,iGBS后持续到青春期的精神疾病风险增加,包括脑膜炎和败血症。高危的特殊精神疾病包括焦虑、强迫症、自闭症和注意缺陷多动障碍。早产、母亲妊娠期糖尿病和母亲受教育程度低会进一步增加任何精神疾病的风险,而孩子的性别则不会。
{"title":"Long-term risk of psychiatric disorders in childhood and adolescence following neonatal invasive group B Streptococcus disease—A Danish cohort study","authors":"Malene Risager Lykke ,&nbsp;Henrik Toft Sørensen ,&nbsp;Joy Elisabeth Lawn ,&nbsp;Erzsébet Horváth-Puhó","doi":"10.1016/j.jinf.2025.106463","DOIUrl":"10.1016/j.jinf.2025.106463","url":null,"abstract":"<div><h3>Objectives</h3><div>The long-term risk of child and adolescent psychiatric disorders (PDs) after neonatal invasive group B <em>Streptococcus</em> disease (iGBS) and the modifying factors are poorly understood.</div></div><div><h3>Methods</h3><div>A population-based matched cohort study, including 1548 infants with iGBS diagnosed during the first 3 months of life from 1997 through 2020 and follow-up until 2022, based on data from Danish national health and administrative registers. A general population comparison cohort of infants without iGBS was randomly sampled and matched 1:10 by sex, the child’s birth year and month, and gestational age (n= 15,345).</div></div><div><h3>Results</h3><div>The cumulative incidence proportion (CIP) with 95% confidence intervals (CIs) of any PD was 21.1% (95% CI 18.7–23.7) in infants exposed to iGBS (88% sepsis, 12% meningitis) and 16.2% (95% CI 15.5–17.0) in the comparison cohort. The 18-year CIP of PD was higher for infants exposed to iGBS meningitis compared to iGBS sepsis. The adjusted hazard ratio for PD in infants with iGBS was 1.41 (95% CI 1.23–1.62).</div></div><div><h3>Conclusions</h3><div>iGBS in early infancy is a risk factor for PDs, especially iGBS meningitis. Premature birth, gestational diabetes, and low maternal education increased the risk of any PD further.</div></div><div><h3>Summary</h3><div>Group B <em>Streptococcus</em> (<em>Streptococcus agalactiae</em>) remains the leading cause of neonatal, invasive disease and is associated with high mortality and risk of neurodevelopmental impairments. Scarce data exist regarding the long-term risk of psychiatric disorders following invasive group B <em>Streptococcus</em> disease in early infancy (iGBS), especially following sepsis. In this Danish national cohort study, we investigated the association of iGBS and the risk of psychiatric disorders until adolescence and early adulthood. We investigated to which extent premature birth, sex (at birth), maternal socioeconomic position or gestational diabetes were modifying the association between iGBS and psychiatric disorders.</div><div>Our study found an increased risk of psychiatric disorders persisting into adolescence following iGBS, including both meningitis and sepsis. Specific psychiatric disorders with elevated risk included anxiety, obsessive-compulsive disorder, autism, and attention deficit hyperactivity disorder. Premature birth, maternal gestational diabetes, and low maternal education further increased the risk of any psychiatric disorders, whereas the child’s sex did not.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106463"},"PeriodicalIF":14.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic chemoprophylaxis for close contacts of invasive group A streptococcus in community settings: Evidence review 在社区环境中对侵入性 A 组链球菌密切接触者进行抗生素化学预防:证据综述。
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-13 DOI: 10.1016/j.jinf.2025.106468
Vicky Watts , Martine Usdin , Rachel Mearkle , Shiranee Sriskandan , Rebecca Cordery , Sally Millership , Vanessa Saliba , Claire Edmundson , Anjali Pai , Colin S. Brown , Sooria Balasegaram , Theresa Lamagni , Valerie Decraene , The working group for the UK guidelines for the management of contacts of invasive group A streptococcus (iGAS) infection in community settings

Objectives

Revised UK guidelines for the management of contacts of invasive group A Streptococcus (iGAS) infection in community settings were published in December 2022. We present the findings of a narrative review which informed the public health recommendations around the provision of antibiotic chemoprophylaxis detailed in the updated guidelines.

Methods

We conducted a literature review of studies reporting the risk of iGAS infection associated with specific risk factors.

Results

There was strong epidemiological evidence for an increased risk of iGAS infection in contacts who are older individuals, post-partum women, neonates and individuals with chickenpox infection; evidence on the impact of influenza co-infection, injecting drug use or being homeless in increasing risk of iGAS infection was less robust.

Conclusions

The guidelines made recommendations to offer chemoprophylaxis to close contacts of iGAS cases who are aged ≥75 years, pregnant ≥37 weeks gestation, post-partum, neonates or those with a recent history of, or current chickenpox infection. Systematic data collection evaluating the use of chemoprophylaxis and other control measures is recommended.
目的:修订后的英国社区环境中侵袭性A群链球菌(iGAS)接触者管理指南于2022年12月发布。我们提出了一项叙述性综述的研究结果,该综述为更新指南中详细介绍的提供抗生素化学预防的公共卫生建议提供了信息。方法:我们对报道iGAS感染风险与特定危险因素相关的研究进行了文献综述。结果:有强有力的流行病学证据表明,老年人、产后妇女、新生儿和水痘感染者的接触者感染iGAS的风险增加;关于流感合并感染、注射吸毒或无家可归对iGAS感染风险增加的影响的证据不那么充分。结论:指南建议对年龄≥75岁、妊娠≥37周、产后、新生儿或近期有水痘史或目前有水痘感染的iGAS病例密切接触者给予化学预防。建议系统地收集数据,评估化学预防和其他控制措施的使用情况。
{"title":"Antibiotic chemoprophylaxis for close contacts of invasive group A streptococcus in community settings: Evidence review","authors":"Vicky Watts ,&nbsp;Martine Usdin ,&nbsp;Rachel Mearkle ,&nbsp;Shiranee Sriskandan ,&nbsp;Rebecca Cordery ,&nbsp;Sally Millership ,&nbsp;Vanessa Saliba ,&nbsp;Claire Edmundson ,&nbsp;Anjali Pai ,&nbsp;Colin S. Brown ,&nbsp;Sooria Balasegaram ,&nbsp;Theresa Lamagni ,&nbsp;Valerie Decraene ,&nbsp;The working group for the UK guidelines for the management of contacts of invasive group A streptococcus (iGAS) infection in community settings","doi":"10.1016/j.jinf.2025.106468","DOIUrl":"10.1016/j.jinf.2025.106468","url":null,"abstract":"<div><h3>Objectives</h3><div>Revised UK guidelines for the management of contacts of invasive group A <em>Streptococcus</em> (iGAS) infection in community settings were published in December 2022. We present the findings of a narrative review which informed the public health recommendations around the provision of antibiotic chemoprophylaxis detailed in the updated guidelines.</div></div><div><h3>Methods</h3><div>We conducted a literature review of studies reporting the risk of iGAS infection associated with specific risk factors.</div></div><div><h3>Results</h3><div>There was strong epidemiological evidence for an increased risk of iGAS infection in contacts who are older individuals, post-partum women, neonates and individuals with chickenpox infection; evidence on the impact of influenza co-infection, injecting drug use or being homeless in increasing risk of iGAS infection was less robust.</div></div><div><h3>Conclusions</h3><div>The guidelines made recommendations to offer chemoprophylaxis to close contacts of iGAS cases who are aged ≥75 years, pregnant ≥37 weeks gestation, post-partum, neonates or those with a recent history of, or current chickenpox infection. Systematic data collection evaluating the use of chemoprophylaxis and other control measures is recommended.</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106468"},"PeriodicalIF":14.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral ADC189 for adults and adolescents with uncomplicated influenza 口服 ADC189 治疗成人和青少年非复杂性流感。
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-13 DOI: 10.1016/j.jinf.2025.106472
Jingya Zhao , Guoping Sheng , Yingqi Lyu , Yilan Sun , Sikui Wang , Xiaolin Chen , Feng Ye , Lin Chen , Xiaowei Xu , Hong Wang , Bin Wu , Chunxian Peng , Min Deng , Lihong Qu , Xuehong Jiang , Junyan Hu , Yan Feng , Yongzhong Li , Jie Peng , Weiyang Li , Jieming Qu

Objectives

ADC189 is a novel anti-influenza virus inhibitor. In this study, we aimed to evaluate the safety and efficacy of ADC189 in outpatients with uncomplicated influenza infection.

Methods

In the phase 2 trial, we assigned patients in a 2:2:1 ratio to receive either single dose 15-mg or 45-mg of ADC189 or placebo. In the phase 3 part, participants were randomized in a 2:1 ratio to receive 45-mg of ADC189 or placebo. The primary endpoint was the time to alleviation of influenza symptoms in the intention-to-treat infected population.

Results

In the phase 2 trial that had 150 participants, the median time for virus RNA clearance was shorter in both ADC189 groups (15-mg group, 50·7 h; 45 mg-group, 45·8 h) compared to the placebo group (73·4 h; p=0·69 and 0·016, respectively). 617 participants were enrolled in the phase 3 trial. The median time to symptom alleviation was 50·0 h (95% CI, 44·6 to 59·3) with ADC189, as compared with 68·1 h (95% CI, 62·8 to 84·4) with placebo (p<0·0001). By 1 day after initiation, the decrease in viral load from baseline was greater in the ADC189 group than in the placebo group (2·316 and 1·049 log10 virus copies per milliliter, respectively). Most adverse events were mild or moderate.

Conclusions

A single-dose ADC189 shorten the time to the resolution of symptoms among adults and adolescents with uncomplicated influenza, without evident safety concerns.
(Funded by Jiaxing AnDiCon Biotech Co., Ltd, Zhejiang, China; ChiCTR number, 20230137, and ClinicalTrials. gov number, NCT 06342921.)
目的:ADC189是一种新型抗流感病毒抑制剂。在本研究中,我们旨在评估ADC189对门诊无并发症流感感染患者的安全性和有效性。方法:在2期试验中,我们以2:2:1的比例分配患者接受单剂量15mg或45mg ADC189或安慰剂。在第三阶段,参与者以2:1的比例随机接受45毫克ADC189或安慰剂。主要终点是意图治疗的感染人群中流感症状缓解的时间。结果:在有150名参与者的2期试验中,两组ADC189清除病毒RNA的中位时间都更短(15 mg组,50.7小时;45毫克组,45.8小时)与安慰剂组(74.3小时;P值分别为0.69和0.016)。617名参与者参加了3期试验。ADC189缓解症状的中位时间为50.0小时(95% CI, 44.6至59.3),而安慰剂组为68.1小时(95% CI, 62.8至88.4)(每毫升分别为p10个病毒拷贝)。大多数不良事件为轻度或中度。结论:单剂量ADC189可缩短成人和青少年无并发症流感患者症状消退的时间,无明显的安全性问题。(浙江省嘉兴市安迪康生物科技有限公司资助;ChiCTR编号20230137,临床试验。网址:NCT06342921)。
{"title":"Oral ADC189 for adults and adolescents with uncomplicated influenza","authors":"Jingya Zhao ,&nbsp;Guoping Sheng ,&nbsp;Yingqi Lyu ,&nbsp;Yilan Sun ,&nbsp;Sikui Wang ,&nbsp;Xiaolin Chen ,&nbsp;Feng Ye ,&nbsp;Lin Chen ,&nbsp;Xiaowei Xu ,&nbsp;Hong Wang ,&nbsp;Bin Wu ,&nbsp;Chunxian Peng ,&nbsp;Min Deng ,&nbsp;Lihong Qu ,&nbsp;Xuehong Jiang ,&nbsp;Junyan Hu ,&nbsp;Yan Feng ,&nbsp;Yongzhong Li ,&nbsp;Jie Peng ,&nbsp;Weiyang Li ,&nbsp;Jieming Qu","doi":"10.1016/j.jinf.2025.106472","DOIUrl":"10.1016/j.jinf.2025.106472","url":null,"abstract":"<div><h3>Objectives</h3><div>ADC189 is a novel anti-influenza virus inhibitor. In this study, we aimed to evaluate the safety and efficacy of ADC189 in outpatients with uncomplicated influenza infection.</div></div><div><h3>Methods</h3><div>In the phase 2 trial, we assigned patients in a 2:2:1 ratio to receive either single dose 15-mg or 45-mg of ADC189 or placebo. In the phase 3 part, participants were randomized in a 2:1 ratio to receive 45-mg of ADC189 or placebo. The primary endpoint was the time to alleviation of influenza symptoms in the intention-to-treat infected population.</div></div><div><h3>Results</h3><div>In the phase 2 trial that had 150 participants, the median time for virus RNA clearance was shorter in both ADC189 groups (15-mg group, 50·7 h; 45 mg-group, 45·8 h) compared to the placebo group (73·4 h; <em>p</em>=0·69 and 0·016, respectively). 617 participants were enrolled in the phase 3 trial. The median time to symptom alleviation was 50·0 h (95% CI, 44·6 to 59·3) with ADC189, as compared with 68·1 h (95% CI, 62·8 to 84·4) with placebo (<em>p</em>&lt;0·0001). By 1 day after initiation, the decrease in viral load from baseline was greater in the ADC189 group than in the placebo group (2·316 and 1·049 log<sub>10</sub> virus copies per milliliter, respectively). Most adverse events were mild or moderate.</div></div><div><h3>Conclusions</h3><div>A single-dose ADC189 shorten the time to the resolution of symptoms among adults and adolescents with uncomplicated influenza, without evident safety concerns.</div><div>(Funded by Jiaxing AnDiCon Biotech Co., Ltd, Zhejiang, China; ChiCTR number, 20230137, and ClinicalTrials. gov number, NCT 06342921.)</div></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106472"},"PeriodicalIF":14.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged infusion of β-lactam antibiotics for the treatment of febrile neutropenia 长期输注β-内酰胺类抗生素治疗发热性中性粒细胞减少症。
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-13 DOI: 10.1016/j.jinf.2025.106464
J. Laporte-Amargos, C. Tebé, J. Carratalà, C. Gudiol
{"title":"Prolonged infusion of β-lactam antibiotics for the treatment of febrile neutropenia","authors":"J. Laporte-Amargos,&nbsp;C. Tebé,&nbsp;J. Carratalà,&nbsp;C. Gudiol","doi":"10.1016/j.jinf.2025.106464","DOIUrl":"10.1016/j.jinf.2025.106464","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106464"},"PeriodicalIF":14.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergence of Oropouche virus infection in Matanzas, Cuba, 2024 2024年在古巴马坦萨斯出现的Oropouche病毒感染。
IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2025-03-12 DOI: 10.1016/j.jinf.2025.106470
Berta María Bello-Rodríguez, Junior Vega-Jiménez , Roberto Cañete , Alfonso J. Rodriguez-Morales
{"title":"Emergence of Oropouche virus infection in Matanzas, Cuba, 2024","authors":"Berta María Bello-Rodríguez,&nbsp;Junior Vega-Jiménez ,&nbsp;Roberto Cañete ,&nbsp;Alfonso J. Rodriguez-Morales","doi":"10.1016/j.jinf.2025.106470","DOIUrl":"10.1016/j.jinf.2025.106470","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"90 4","pages":"Article 106470"},"PeriodicalIF":14.3,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Infection
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1